Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

Merck said on Monday it would pay up to $2.13 billion under a ​global licensing deal with China's SciBrunch Therapeutics ‌for rights to develop, manufacture and sell an experimental cancer treatment.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。